Atticus Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Atticus Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2	Closed	-$1.05K	–	525
2025 Q2	$1.05K	Buy	+2	New	+$1.12K	﹤0.01%	599
2023 Q1	–	Sell	-3	Closed	-$2.16K	–	577
2022 Q4	$2.16K	Sell	3 -6	-67%	-$4.43K	﹤0.01%	460
2022 Q3	$5K	Hold	9	–	–	﹤0.01%	439
2022 Q2	$5K	Hold	9	–	–	﹤0.01%	471
2022 Q1	$6K	Buy	9 +4	+80%	+$2.53K	﹤0.01%	453
2021 Q4	$3K	Sell	5 -61	-92%	-$37.5K	﹤0.01%	407
2021 Q3	$40K	Sell	66 -2	-3%	-$1.24K	0.02%	260
2021 Q2	$38K	Hold	68	–	–	0.02%	251
2021 Q1	$32K	Sell	68 -58	-46%	-$28.2K	0.02%	242
2020 Q4	$61K	Hold	126	–	–	0.03%	192
2020 Q3	$71K	Hold	126	–	–	0.04%	159
2020 Q2	$79K	Buy	126 +3	+2%	+$1.7K	0.05%	144
2020 Q1	$60K	Buy	+123	New	+$50.7K	0.05%	162

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Atticus Wealth Management's REGN Position: Q3 2025 in Review

Atticus Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 2 shares — an estimated $1.05K sold.

Atticus Wealth Management first reported a position in REGN in Q1 2020 and held it in 13 quarters. The position peaked at $79K in Q2 2020. 1,245 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

Atticus Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Atticus Wealth Management sold 2 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $1.05K.
Atticus Wealth Management first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 13 quarters.
Atticus Wealth Management's Regeneron Pharmaceuticals position peaked at $79K in Q2 2020.
1,245 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Atticus Wealth Management's 13F filing for Q3 2025, filed 7 Nov 2025.